Translational Research Projects

NSF ART NJIT Cooperative Agreement - 2024
This project supports acceleration of translation research and innovation that will promote the advancement of scientific progress along with prosperity and welfare of the nation through the enhancement of translational research.

NJIT Research, Innovation and Entrepreneurship (RITE) Ecosystem
TITA Seed Grand Program collaboration with the NSF ART program

Technology Innovation Translation Acceleration (TITA)
The NJIT Technology Innovation Translation and Acceleration (TITA) Seed Grant program will enable faculty and students to successfully accelerate the translation of their innovation to enterprise development and business incubation. The TITA seed grant program will foster entrepreneurial pathways from research and innovation to business and value creation with the acquisition of intellectual property, market validation, and engagement of stakeholders towards commercialization.

TITA Seed Grant Awards

NJIT Technology Innovation Translation and Acceleration (TITA) seed grants are funded in three phases of $25,000 each with a total potential funding of up to $75,000 as following:

Phase-1 (Up to $25,000): Technology Innovation Translation Research and Proof of Validation: The Phase-1 proposal must incorporate collaborative research and partnership with at least one external stakeholder from industry, academia, community or local government organizations, federal labs, or professional user groups (such as physicians in hospital or private practice for medical devices). The objectives of the Phase-1 proposal must include market research for unmet need(s), developing prototype devices/technology, translational research for application validation, and assessment of all risks associated with bringing the application to market, especially with respect to competition and future growth. 

Phase-2 (Up to $25,000): Technology Innovation Acceleration to Entrepreneurship: The Phase-2 funding will focus on the development of pre-commercial prototypes of devices or technology, scalable validation, and business plans and technology transfer to an existing company or forming a new start-up company establishing market channels.  This phase, often called the early incubation stage, will include advanced market validation studies (such as early clinical trials for validation of potential medical devices). The Phase-2 goals must also include development of collaborative partnership-based business models and strategies to attract interest from external entrepreneurs, investors or a commercial entity for licensing and commercialization.

Phase-3 (Up to $25,000): Advanced Technology Innovation Acceleration to Commercialization: The collaborative partnership-based Phase-3 proposal will focus on developing commercialization plans with advanced commercialization-ready technology or product(s) and additional regulatory, business, marketing, and risk management.  This phase will also include larger scalable technology validation, market trials (such as early clinical trials for medical devices) and user-acceptance studies towards submission of investment proposal and grants to secure future funding for commercialization from the NJIT Investment Fund, an angel investment fund, NSF TIP or similar grant program. 

Announcement

NJIT Technology Innovation Translation and Acceleration (TITA) Program
TITA-2025 Seed Grant Awards

The NJIT Technology Innovation Translation and Acceleration (TITA) Seed Grant program will enable faculty and students to successfully accelerate the translation of their innovation to enterprise development and business incubation. The TITA seed grant program will foster entrepreneurial pathways from research and innovation to business and value creation with the acquisition of intellectual property, market validation, and engagement of stakeholders towards commercialization.

The TITA Seed Grants will increase awareness of the potential commercial benefits at earlier stages of the translation and market validation process and allow researchers and stakeholders to collaborate for entrepreneurial success. It will also help faculty to submit competitive translational research proposals to external grant funding opportunities.

We are pleased to award five TITA-2024 seed grants funded for $75,000 each in this cycle. The TITA seed grant program was initiated last year with four TITA-2023 seed grants with technology innovation translational research projects which are now transitioning to Phase-3 of the program for market validation towards entrepreneurial pathways. Thus, there are currently 9 innovative technologies funded for $75,000 each under the TITA program for translational research and market validation for potential tech transfer and commercialization activities. The TITA program that was initiated in Fall 2022 with the NJ State and institutional funding is now supported by the Accelerating Translational Research (ART) grant funded by the NSF Technology and Innovation Partnership (TIP) directorate for further enhancement and expansion through the NJIT Center for Translational Research which will be formally established in early Spring 2024.

Congratulations to All 2025 TITA Seed Grant Awardees!

NJIT Technology Innovation Translation and Acceleration (TITA) Program
TITA-2025 Seed Grants

Title of the Technology: n-Fast - A Nanotechnology Approach to Developing Fast Dissolving Active Pharmaceutical Ingredients (APIs)

Proposers and Affiliations: Somenath Mitra, PhD, Distinguished Professor, Chemistry and Environmental Sciences, NJIT

Partnership Team: Sai Rangarao, Senior Vice President of Commercialization, Pelthos Therapeutics; Marc Long, Executive Vice President, Research & Development, Clinical & Medical Affairs, MTF Biologics

Executive Summary:
The United States maintains a dominant position in the global pharmaceutical industry, accounting for 42.6% of the $1.48 trillion global pharmaceutical market. The country hosts some of the largest pharmaceutical companies globally, and American consumers have access to the most cutting-edge pharmaceutical products worldwide. A significant challenge currently confronting the pharmaceutical industry and drug development pertains to a substantial proportion (40 to 70%) of active pharmaceutical ingredients (API) exhibiting low water solubility, resulting in poor bioavailability and often therapeutic ineffectiveness. These hydrophobic molecules fall within the Biopharmaceutics Classification System (BCS) categories II and IV drugs. In light of this, the global market for BCS Class II and IV drugs could range from $600 billion to $1.036 trillion. The text later presents selected candidate APIs and their respective market sizes.

In addition to developing new drug molecules, the drug delivery market is experiencing a Compound Annual Growth Rate (CAGR) of 6.5%, with projections to exceed $375 billion by 2027 (see Table 1). Another important consideration is the growing demand for rapid drug release, as illustrated in Table 2, which anticipates this market to reach over $32 billion by 2027. Faster release is especially critical for BCS Class II and Class IV drugs, and the accelerated release proposed here will further propel the growth of this market segment. In summary, these represents our target market.

There are several conventional technologies that are employed to enhance the solubility, dissolution, and bioavailability of poorly soluble drugs. These are: Particle Size Reduction, Solid dispersions, Lipid based delivery systems, co-crystallization and complex formation. Using TITA Phase I funding we have been able to compare our technology to our competition, the data is presented in our progress report.

We have developed a nanotechnology approach referred to as n-Fast to enhance the bioavailability and effectiveness of Active Pharmaceutical Ingredient (API) crystals by improving their water solubility, essentially creating a fast-dissolving version of the drug (1-10). Our technology aims to reformulate various insoluble APIs, falling under BCS Class II and IV, with bioabsorbable, functionalized nanoparticles (FNPs) featuring surface hydrophilization to enhance solubility, and ultimately efficacy. We propose the direct incorporation of FNPs into drug crystals during their formation in a way that preserves the crystal structure, polymorph, and physicochemical properties. The mechanism of fast dissolution
Our initial work involved functionalized carbon nanotubes (fCNTs) and nano graphene oxide (nGO) as FNPs. While fCNTs and nGO showed excellent results, their potential cytotoxicity raised significant concerns. Consequently, partially using Phase I TITA funds we have commenced the development of FNPs using FDA-approved bioabsorbable polymers.

Title of the Technology:  Functional Nano-carbon Enhanced Phase Change Materials (PCMs)
for Improved Thermal Properties, and Long-term Durability

Proposers and Affiliations: Eon Soo Lee, Ph.D., Associate Professor, Mechanical and Industrial Engineering, NJIT

Partnership Team: Swati Agarwala, Ph.D., Technical Solution Manager, Phase Change Solutions Inc.

Executive Summary: 

Problem Statement: The need for effective thermal energy management is growing across sectors such as insulated packaging, cold chain logistics, temperature-sensitive product storage, building materials, and electronics cooling, aiming to boost energy and cost efficiency. As a result, demand for phase change materials (PCMs) that enhance thermal energy storage and management is on the rise. However, widespread adoption of PCMs in these fields remains limited due to the lack of materials that are economical, safe, environmentally friendly, high in heat storage capacity, and durable for long-term use.
Unmet Market Need: As the application of PCMs continues to grow across a wide range of industries, there is an increasing demand for materials that possess specific properties tailored to the unique needs of these applications. However, the producers of PCMs are facing significant challenges due to the limited variety of materials available that meet both environmental and safety regulations. These stringent regulations, which are designed to ensure that materials are safe for human health and the environment, are restricting the ability of manufacturers to develop and offer a broader range of PCMs. As a result, there is a growing need in the market for more diverse PCM options that not only comply with these regulatory standards but also exhibit a high degree of versatility, making them suitable for a wider array of applications.
Technology Innovation and Solution: The PI proposes developing advanced PCMs with superior thermal properties and operational durability by integrating various PCMs, particularly bio-based types, with functional nano-carbon materials. As shown schematically in Figure 1, functional nano-carbon materials are integrated with a base PCM to ensure both physical and chemical interactions, enabling enhancement and adjustment of thermal characteristics to meet specific application requirements. This approach aligns with regulatory requirements, as the base PCMs can be selected from environmentally safe materials. The enhancements are achieved through the specific functionalities of nano-carbon materials tailored to application needs, thereby expanding material choices across a wide range of applications.
Competition and Competitive Advantage: The proposed PCMs are cost-effective, safe, and environmentally friendly. By leveraging interactions between nano-carbon materials and carefully selected base PCMs, these advanced PCMs achieve targeted thermal properties while preserving structural integrity, enhancing durability during operation.

Title of the Technology: Rapid Detection of Per- and Polyfluoroalkyl Substances (PFAS) Using Paper Spray-Based Mass Spectrometry

Proposers and Affiliations: Hao Chen, Ph.D., Professor, Department of Chemistry & Environmental Science, NJIT

Partnership Team: Charmi Chande, CEO, PFASolve, LLC

Executive Summary:
PFAS are of great concern due to their persistence, toxicity, and potential for bioaccumulation in the environment. Exposure to per-fluorooctanoic acid (PFOA) and per-fluorosulphonic acid (PFOS), two specific PFAS compounds, has been linked to adverse effects on fetal development, such as decreased birth weight, and has also been shown to suppress vaccine responses, resulting in lower serum antibody concentrations in children. In addition, studies have shown that the presence of PFAS can increase the production of reactive oxygen species (ROS) through oxidative stress, induce DNA damage, and cause cancer and inflammation.14 Traditional PFAS analysis by mass spectrometry (MS) is time-consuming and takes a few hours according to the EPA method referred by 533 where prior run in LC-MS takes laborious sample preparation by solid phase extraction (e.g., extraction and desalting) technique. In the PI’s laboratory at NJIT, we developed a fast detection of PFAS by paper spray (PS)-based MS techniques, which only takes 1-3 min for detection of PFAS from a variety of different samples (water samples, soils, food packaging materials, etc.) In addition, our method is highly sensitive (limits of detection:1-4 ppt for PFOA and PFOS). These results suggest the high potential of our new technique in real-world environmental screening and analysis of PFAS. This work was published in Journal of Hazardous Materials (JHM, 2024, 465, 133366; Journal impact factor 14.2 in 2021). This TITA grant aims to 1) Enhance the sensitivity of PFAS detection protocol to go beyond 1 ppt, which would be crucial for detecting PFAS in urine to track exposure patterns and evaluate kidney function's role in PFAS elimination in the future. 2) Build a position-controlled PSI and DPS platform for gaining high signal reproducibility for improving quantitative PFAS analysis 3) Identify the key partner and develop the PFAS detection protocol compatible with on-site MS. At the conclusion of the TITA grant, we are expected to develop a more robust, sensitive, and selective protocol for PFAS detection from real-world samples, such as drinking water. Additionally, the protocol must be optimized for compatibility with an on-site mass spectrometer developed by our identified key partner.

Title of the Technology: Revolutionizing Cardiac Care with Heart Energy
(Funded as Collaborative Early Research Translation (CERT) Seed Grant).

Proposers and Affiliations: Lin Dong, PhD, Assistant Professor, Department of Mechanical & Industrial Engineering, NJIT

Partnership Team: Huzaifa Shakir, MD, MHA, FACS; Associate Professor, Department of Cardiac Surgery, Rutgers-New Jersey Medical School

Executive Summary:
Heart disease is the leading cause of death globally. The global cardiovascular devices market was valued at $63.49 billion in 2024 and is projected to reach $104.08 billion by 2031, with a compound annual growth rate (CAGR) of 7.03% during this period. This growth is primarily driven by the high prevalence of cardiovascular diseases, an aging population, and the increasing demand for innovative, cost-effective treatment options that minimize the need for surgical interventions. Cardiac pacemakers and implantable cardioverter-defibrillators are effective tools for treating heart block and ventricular dysrhythmias in patients with heart disease. Notably, leadless pacemakers (LPs), which are 90% smaller than traditional transvenous pacemakers, have demonstrated excellent safety and efficacy in both short-term and intermediate follow-ups. However, the clinical utility of all those cardiovascular devices is compromised by the limited battery life.

Studies show that over 40% of LPs fail within three years, despite manufacturers' claims of longer longevity, while the average post-implantation longevity of traditional pacemaker recipients has increased to over 15 years. This creates a significant mismatch that impacts clinical practice and incurs substantial economic costs. Battery depletion or malfunction necessitates new implantations due to limited retrieval experience. Although LPs represent an advancement in cardiac pacing, they also come with complications. Clinical trials report major issues, such as device dislodgement and cardiac perforation, as well as infection at the implantation site, which can lead to longer hospital stays. Therefore, the risks, costs, and complications of LP surgeries highlight the need for alternative power solutions to extend the longevity of cardiovascular devices, reduce the need for replacements and surgeries, and improve patient care.

Dr. Dong’s lab is developing advanced energy harvesting technology that significantly extends the lifespan of LPs by transforming the heart's natural mechanical energy into electrical power. Designed to revolutionize LPs, this technology leverages advanced functional nanomaterials, innovative geometric designs, and seamless integration with existing systems to significantly enhance patient care. The key breakthrough lies in the incorporation of cardiac energy harvesters optimized for the heart's dynamic environment. By leveraging flexible, biocompatible materials to capture even subtle cardiac motions, this technology converts them into electrical energy to sufficiently autonomously power the pacemakers. The energy harvesters maintain the compact form factor of existing LPs while enhancing functionality through sustainable energy solutions.
This cardiac energy harvesting strategy addresses the most pressing challenges of energy consumption and the need for pacemaker replacement surgeries. With anticipated success, it promises to transform the lives of individuals facing the burden of periodic pacemaker replacements, offering longer-lasting implantable biomedical devices that reduce both surgical risks and costs. Ultimately, this innovation not only enhances patient outcomes but also elevates the overall quality of life, marking a significant leap forward in medical technology.

TITA-2024 Seed Projects Announcement 

TITA-2023 Seed Projects Announcement

Announcement

Collaborative Early Research Translation (CERT) Seed Grant Awards FY2026 (July 2025 - June 2026)

Congratulations to All Awardees!

To accelerate NJIT’s trajectory towards increased collaborative research and innovation funding for higher faculty and student success, a new strategic initiative, Collaborative Early Research Translation (CERT) Seed Grants supported by the U.S. National Science Foundation Accelerating Research Translation (ART) program was launched in 2023 to invest in translational research of high potential impact. These CERT seed grants will initiate early translation of research and innovation, working collaboratively with an external partner, towards developing proof-of-feasibility and potential intellectual property to build foundation to submit competitive proposals for external research translation acceleration funding opportunities, or internal NJIT TITA (Technology Innovation Translation Acceleration) seed grants for further advancement in translational research and market validation.

NJIT’s internal seed funding opportunities are critical components of the strategic Research, Innovation and Technology Entrepreneurship (RITE) ecosystem as outlined in the 2030 Strategic Plan. We are pleased to announce the award of 5 CERT Seed Grants for very exciting translational research projects with external collaborators and partners. Each CERT Seed Grant is awarded $25,000 with a total investment of $125,000 which is partially funded by the NSF Accelerating Research Translation (ART) award and through the NJIT Center for Translational Research (CTR).
Congratulations to all recipients of the FY2026 CERT Seed Grants (listed below)!

Newark College of Engineering

NJIT Principal Investigator: Farid Alisafaei, Mechanical Engineering
Collaborator/Partner: Guy Genin, Professor
Collaborator/Partner Affiliation: Washington University St. Louis
CERT Project Title: DermaMech: Kirigami-Inspired Skin Grafts that Enhance Graft Success and Reduce Donor Site Morbidity
CERT Funding: $25,000

NJIT Principal Investigator: Rayan Hassane Assaad, Civil and Environmental Engineering
Collaborator/Partner: Wei Wang, CEO and founder Operating Officer
Collaborator/Partner Affiliation: UrbanTech Consulting Engineering
CERT Project Title: An Intelligent Unmanned Aerial Vehicle (UAV) Drone Robotic System Featuring Dynamic Sensor Reorientation Apparatus, Multimodal Sensor Fusion, and Artificial Intelligence (AI) for Smart and Automated Infrastructure Asset Management
CERT Funding: $25,000

NJIT Principal Investigator: Xiaobo Li, Biomedical Engineering
Collaborator/Partner: Qinyin Qiu, Assistant Professor
Collaborator/Partner Affiliation: School of Health Professions, Rutgers University
CERT Project Title: Toward the Development of an Interactive Virtual Environment for Motor Activity Deficits Assessment and Rehabilitation in Children with ADHD
CERT Funding: $25,000

Jordan Hu College of Science and Liberal Arts

NJIT Principal Investigator: Sara Casado Zapico, Chemistry and Environmental Science
Collaborator/Partner: Victoria Dominguez, Assistant Professor
Collaborator/Partner Affiliation: Lehman College-CUNY
CERT Project Title: Bonepihist: new biomarkers for osteoporosis prediction and prognosis
CERT Funding: $25,000

Martin Tuchman School of Management

NJIT Principal Investigator: Jae-Hyuck Park, MTSM
NJIT Co-Principal Investigators: Jim Shi, MTSM
Collaborator/Partner: Bryan Santos, Director of Corporate Development at Aerofarms
Collaborator/Partner Affiliation: AeroFarms
CERT Project Title: AgriTech in the era of AI: Vertical Farming Innovation and Implications
CERT Funding: $25,000

Collaborative Early Research Translation (CERT) Seed Grants